Vita Life Sciences Limited

CHIA:VLS Stock Report

Market Cap: AU$116.8m

Vita Life Sciences Valuation

Is VLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VLS (A$2.06) is trading below our estimate of fair value (A$11.73)

Significantly Below Fair Value: VLS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VLS?

Key metric: As VLS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VLS. This is calculated by dividing VLS's market cap by their current earnings.
What is VLS's PE Ratio?
PE Ratio12.4x
EarningsAU$9.39m
Market CapAU$116.81m

Price to Earnings Ratio vs Peers

How does VLS's PE Ratio compare to its peers?

The above table shows the PE ratio for VLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.7x
VIT Vitura Health
16.6xn/aAU$57.0m
ECS ECS Botanics Holdings
11.4xn/aAU$23.2m
NEU Neuren Pharmaceuticals
13.8x-9.9%AU$1.6b
EZZ EZZ Life Science Holdings
17.2x17.9%AU$111.1m
VLS Vita Life Sciences
12.4xn/aAU$116.8m

Price-To-Earnings vs Peers: VLS is good value based on its Price-To-Earnings Ratio (12.4x) compared to the peer average (14.4x).

Price to Earnings Ratio vs Industry

How does VLS's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

24 CompaniesPrice / EarningsEstimated GrowthMarket Cap
VLS 12.4xIndustry Avg. 22.5xNo. of Companies80PE01632486480+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: VLS is good value based on its Price-To-Earnings Ratio (12.4x) compared to the Global Pharmaceuticals industry average (22.5x).

Price to Earnings Ratio vs Fair Ratio

What is VLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VLS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VLS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$37.9m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

7D

0%

1Y

6.1%

AVITA Medical

US$338.4m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.91

7D

-0.3%

1Y

18.5%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.63

7D

1.6%

1Y

-18.5%